962 related articles for article (PubMed ID: 15701909)
1. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
[TBL] [Abstract][Full Text] [Related]
2. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
Harenberg J; Ingrid J; Tivadar F
Isr Med Assoc J; 2002 Nov; 4(11):1003-5. PubMed ID: 12489490
[TBL] [Abstract][Full Text] [Related]
3. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.
Colwell CW; Berkowitz SD; Lieberman JR; Comp PC; Ginsberg JS; Paiement G; McElhattan J; Roth AW; Francis CW;
J Bone Joint Surg Am; 2005 Oct; 87(10):2169-77. PubMed ID: 16203879
[TBL] [Abstract][Full Text] [Related]
4. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
Koscielny J; Kiesewetter H; Jörg I; Harenberg J
Clin Appl Thromb Hemost; 2007 Jul; 13(3):299-307. PubMed ID: 17636192
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
Francis CW; Berkowitz SD; Comp PC; Lieberman JR; Ginsberg JS; Paiement G; Peters GR; Roth AW; McElhattan J; Colwell CW;
N Engl J Med; 2003 Oct; 349(18):1703-12. PubMed ID: 14585938
[TBL] [Abstract][Full Text] [Related]
6. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Huisman MV; Bounameaux H
Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
[TBL] [Abstract][Full Text] [Related]
7. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Mouret P; Rosencher N; Eskilson C; Nylander I; Frison L; Ogren M;
Thromb Haemost; 2003 Feb; 89(2):288-96. PubMed ID: 12574809
[TBL] [Abstract][Full Text] [Related]
8. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
Schulman S; Wåhlander K; Lundström T; Clason SB; Eriksson H;
N Engl J Med; 2003 Oct; 349(18):1713-21. PubMed ID: 14585939
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
Heit JA; Colwell CW; Francis CW; Ginsberg JS; Berkowitz SD; Whipple J; Peters G;
Arch Intern Med; 2001 Oct; 161(18):2215-21. PubMed ID: 11575978
[TBL] [Abstract][Full Text] [Related]
10. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
Albers GW; Diener HC; Frison L; Grind M; Nevinson M; Partridge S; Halperin JL; Horrow J; Olsson SB; Petersen P; Vahanian A;
JAMA; 2005 Feb; 293(6):690-8. PubMed ID: 15701910
[TBL] [Abstract][Full Text] [Related]
11. Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.
Harenberg J; Jörg I; Weiss C
Eur J Clin Pharmacol; 2006 Mar; 62(3):173-7. PubMed ID: 16416154
[TBL] [Abstract][Full Text] [Related]
12. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Evans HC; Perry CM; Faulds D
Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
[TBL] [Abstract][Full Text] [Related]
13. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial.
Francis CW; Davidson BL; Berkowitz SD; Lotke PA; Ginsberg JS; Lieberman JR; Webster AK; Whipple JP; Peters GR; Colwell CW
Ann Intern Med; 2002 Oct; 137(8):648-55. PubMed ID: 12379064
[TBL] [Abstract][Full Text] [Related]
14. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
[TBL] [Abstract][Full Text] [Related]
15. Ximelagatran.
Choudhury A; Goyal D; Lip GY
Drugs Today (Barc); 2006 Jan; 42(1):3-19. PubMed ID: 16511607
[TBL] [Abstract][Full Text] [Related]
16. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.
Harenberg J; Jörg I; Weiss C
Int J Toxicol; 2006; 25(3):165-9. PubMed ID: 16717032
[TBL] [Abstract][Full Text] [Related]
17. [Ximelagatran for treatment of venous thromboembolism].
Harenberg J; Fenyvesi T; Jörg I
Hamostaseologie; 2002 Aug; 22(3):25-9. PubMed ID: 12215758
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
Colwell CW; Berkowitz SD; Davidson BL; Lotke PA; Ginsberg JS; Lieberman JR; Neubauer J; McElhattan JL; Peters GR; Francis CW
J Thromb Haemost; 2003 Oct; 1(10):2119-30. PubMed ID: 14521593
[TBL] [Abstract][Full Text] [Related]
19. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
[TBL] [Abstract][Full Text] [Related]
20. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
Halperin JL;
Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
